# Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

> **NCT05552573** · PHASE1 · UNKNOWN · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** low-dose LYB001
- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (CHO Cell)
- **BIOLOGICAL:** high-dose LYB001

## Key facts

- **NCT ID:** NCT05552573
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-19
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552573, "Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05552573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*